Our SARS kit research began just three days after the SARS-CoV gene sequence was published on April 11, 2003 and we launched our SARS detection system as May 2003. It is the most sensitive, accurate and rapid diagnostic test for SARS developed to date. Collaborations with both local and Beijing universities and hospitals are ongoing to continually improve the accuracy and sensitivity of our kits.
Severe Acute Respiratory Syndrome (SARS) is a new respiratory illness first reported in Southern China in November 2002. The disease has since spread rapidly to infect almost 8,450 people worldwide, as of the beginning of August 2003, according to the World Health Organisation (WHO). The fatality rate is approximately 10%. Little is known about this recent syndrome, which causes variable flu-like symptoms and pneumonia. It is spread by person-to-person contact, although it may also be spread through the air or other unknown mechanisms.
see image on the right) has been reported as associated with SARS. Early detection of the SARS coronavirus (CoV) in infected patients is vital and may prevent the need to quarantine uninfected people. Loss of revenue due to quarantine and travel restrictions may also be minimized, potentially saving billions of dollars. Disease surveillance and routine monitoring would allow the rapid implementation of control measures that would consequently ease the burden on health care workers and related services should another outbreak occur.
- Enhanced real-time PCR (ERT) method, based on the TaqMan* fluorescent PCR technique. This method is highly sensitive and accurate. The SARS CoV primer and probe set has been tested with a large number of clinical specimens and was found to be extremely sensitive as compared with other methods, showing at least 100 times increased sensitivity than ordinary real-time PCR, and 10 million times increased sensitivity in comparison to conventional PCR.
- NASBA technology. Both kits provide all necessary reagents to carry out 50 reactions. Efficiency of the kits can be examined by the positive controls provided. A separate Extraction Module can be used in conjunction with the SARS testing kits. The Extraction Module includes lysis buffer and extraction reagents (sufficient for 50 reactions).
For SARS testing kits ordering or technical details, please submit an online enquiry or contact us.
*TaqMan is a registered trademark of Roche Molecular System, Inc.
| SARS Detection Kits for Clinical Diagnostic | ||||||||||||
|